Clinical trials
Human Papillomavirus clinical trials
Below are recruiting human papillomavirus clinical trials, each written for real people, not researchers. We’re tracking 69 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06650956Recruiting
HPV vaccine and health education for teens in Laos
This trial offers HPV vaccination and sexual health education to 10-13 year old students and out-of-school youth in Laos. It aims to improve health knowledge and vaccination rates.
Muang Sing, ProvinceAges 10–13 - NCT06610773RecruitingPhase 1/Phase 2
Stem cell treatment for high-risk HPV infection
This trial tests whether umbilical cord stem cells can help clear a persistent high-risk HPV infection. It is for women aged 25 to 60 who have had HPV for a while and have not been treated with other HPV drugs recently.
Shanghai, Shanghai MunicipalityAges 25–60 - NCT06198491Enrolling by invitation
HPV education study for women
This study tests how learning more about HPV affects women's beliefs about the virus. It may help you make informed health decisions.
Odunpazari, EskişehirAges 18 years+ - NCT06254911RecruitingPhase 2
Immunotherapy before surgery for HPV-related throat cancer
This trial tests whether giving the drug atezolizumab before surgery can help shrink HPV-related throat cancer and improve outcomes. Atezolizumab helps your immune system fight cancer cells.
Atlanta, GeorgiaAges 18 years+ - NCT07281599Recruiting
Using a pad to screen for cervical precancer
This trial tests whether a special pad you wear during your period can detect signs of cervical precancer. If you are already scheduled for a colposcopy due to an abnormal Pap or HPV test, you might be able to participate.
New Haven, ConnecticutAges 25 years+ - NCT07179315RecruitingPhase 2
Immunotherapy Study for HPV-Positive Head and Neck Cancer
This trial compares two different immunotherapy approaches for people with HPV-positive oropharyngeal cancer who have completed initial treatment like surgery, radiation, or chemotherapy. The goal is to see which option works better to keep the cancer from coming back, and eligibility is determined by a special blood test that detects HPV DNA.
Chicago, IllinoisAges 18 years+ - NCT05799144RecruitingPhase 2
Pembrolizumab plus investigational HPV drugs for throat cancer
This Phase 2 trial studies pembrolizumab (an immune therapy) combined with investigational treatment(s) pBI-11 and TA-HPV for advanced or recurrent oropharyngeal cancer that is HPV-positive and has certain immune marker levels (PD-L1 CPS ≥ 1). It may help your immune system better attack cancer.
Birmingham, AlabamaAges 18 years+ - NCT04226313Recruiting
Home self-swab tests for people not doing cervical screening
This study looks at whether a home self-sampling swab can help people who haven’t joined cervical cancer screening in the past few years. If you qualify, you’ll be asked to collect a swab yourself so it can be tested, aiming to make screening easier to access.
OlomoucAges 30–65 - NCT04422366RecruitingPhase 3
9-valent HPV vaccine study for healthy Chinese women
This trial tests a 9-type HPV vaccine to see how well it works, how it helps the body build protection, and whether it’s safe. It’s for healthy Chinese women who have not had HPV vaccination before and meet specific health and timing requirements.
Liuzhou, GuangxiAges 20–45 - NCT04901351Recruiting
Genetic testing for persistent high-risk HPV after treatment
This study uses a detailed DNA test to look for high-risk HPV in people with long-lasting (chronic) infection after treatment or with return of abnormal cells. It may help improve how clinicians monitor high-risk HPV and decide next steps.
ToulouseAges 18 years+ - NCT05026138Recruiting
Study of severe HPV disease and why it keeps coming back
This study follows people with severe or hard-to-treat HPV-related conditions (and some closely related partners/household contacts) to learn how the virus causes illness and how the immune system responds. It may help doctors better predict who will develop severe disease and guide future treatments.
Bethesda, MarylandAges 3–100 - NCT05539638Recruiting
Testing blood DNA for head and neck squamous cancer
This study looks at how tumor DNA found in a blood sample (a “DNA signal”) relates to head and neck cancer in the oropharynx. It may help doctors understand disease status and improve how they monitor treatment, for both HPV-positive and HPV-negative cancers.
Dundee, DD2 1SGAges 18 years+ - NCT05672927RecruitingPhase 4
Comparing HPV vaccine schedules: 2 doses vs 3 doses
This study compares how well your immune system responds to an HPV vaccine given as either 2 doses or 3 doses in people ages 27–45 who have never had the HPV vaccine. It may help improve HPV prevention strategies and guide the best dose schedule for adults.
Galveston, TexasAges 27–45 - NCT05686226RecruitingPhase 2
Trial tests immune cells targeting HPV-16 cancers
This Phase 2 trial tests an immune-cell treatment (E7 TCR T cells) designed to attack cancers caused by HPV type 16. It may help people whose HPV-16+ cancer has come back or not responded to standard treatment.
Bethesda, MarylandAges 18 years+ - NCT05774561Recruiting
Using blood tests to monitor HPV-related cancer treatment
This study checks whether “liquid biopsies” (blood tests that look for cancer-related signals) can help monitor how HPV-related cancers respond to treatment. It may help doctors spot changes earlier during care.
OlomoucAges 18–99 - NCT05918510Recruiting
Blood and tumor study for virus markers in throat cancer
This study looks at virus-related markers and tiny gene regulators (microRNAs) in tumor tissue from people with certain throat cancers caused by human papilloma virus (HPV). It’s observational, meaning it does not change your treatment, but results may help doctors better understand these cancers and how they behave.
RomeAges 18 years+ - NCT06129253Recruiting
GLOBE-HPV: Study of HPV in communities
This study is trying to find out how many people in different communities have HPV (human papillomavirus). It involves collecting samples and answering questions to help estimate the global burden of HPV.
DhakaAges 9–50 - NCT06223568RecruitingPhase 2
Chemo with or without a vaccine for HPV-related throat cancer
This trial tests whether adding an immunotherapy vaccine (PRGN-2009) to standard chemotherapy before surgery works better than chemotherapy alone for people with newly diagnosed HPV-positive oropharyngeal (head and neck) cancer.
Bethesda, MarylandAges 18–120 - NCT06254846Recruiting
Urine test for HPV cervical cancer screening
This study tests if a urine sample can replace a cervical swab for HPV testing during cervical cancer screening. If it works, it could make screening easier and less uncomfortable.
Saint-EtienneAges 30–65 - NCT06574087Recruiting
Screening for anal cell changes in women with HPV related gynecological disease
This study looks at how often anal cell changes happen in women who have HPV-related gynecological problems. The goal is to find the best way to screen for these changes early.
Gdynia, Pomeranian VoivodeshipAges Any age - NCT06582654Recruiting
Antibody detection in first-void urine
This study looks at a new way to detect HPV antibodies in a urine sample. It is for people who have received the HPV vaccine to help improve testing.
Edegem, AntwerpAges 9–70 - NCT06598475Recruiting
Improving HPV vaccination in Latino teens at health centers
This trial tests a program to help community health centers recommend and boost HPV vaccination rates among Latino adolescents aged 11-12. It aims to support health care providers and staff with education and resources.
Houston, TexasAges 11–17 - NCT06797986RecruitingPhase 1/Phase 2
Vaccine for HPV-positive head and neck cancer
This trial tests an investigational vaccine called BVAC-E6E7 for head and neck cancer caused by HPV types 16 or 18 that has come back or spread. It is for people who have already tried standard treatments like platinum chemo or immunotherapy, or can't take them.
SeoulAges 19 years+ - NCT06642324Recruiting
HPV and genetics in head and neck cancer study
This study looks at how HPV infection and genetic changes relate to head and neck squamous cell carcinoma. If you have this type of cancer, joining could help doctors learn more about the disease and improve future treatments.
Dhaka, Dhaka DivisionAges 18 years+
Hear when a new Human Papillomavirus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for human papillomavirus?
- Yes. Clin2 currently lists 69 recruiting human papillomavirus studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a human papillomavirus trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a human papillomavirus trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.